Primary analysis of Phase III Study Supports Delay of Second Dose of AstraZeneca and Oxford’s COVID-19 Vaccine
Analysis found vaccine to have 76% efficacy after first dose, protection was maintained to second dose with an interval of 12 weeks or more; and efficacy increased to 82%. However, when a second dose was provided less than six weeks after the initial dose, the efficacy was 54.9%.
Source:
Biospace Inc.